Related Experiment Video

Updated: May 25, 2026

A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate
07:31

A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate

Published on: May 3, 2021

PARP-1 inhibition as a targeted strategy to treat Ewing's sarcoma

J Chad Brenner1, Felix Y Feng, Sumin Han

  • 1Michigan Center for Translational Pathology, Department of Pathology, University of Michigan, Ann Arbor, Michigan 48109, USA.

Cancer Research
|January 31, 2012
PubMed

Insights

Ewing's sarcoma family of tumors (ESFT) is sensitive to PARP1 inhibition. Combining a PARP1 inhibitor with temozolamide led to complete tumor responses in preclinical models, suggesting a new therapeutic strategy.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Ewing's sarcoma family of tumors (ESFT) are aggressive cancers often driven by EWS-FLI1 or EWS-ERG genomic fusions.
  • The DNA damage response protein PARP-1 is a potential therapeutic target in various cancers.

Purpose of the Study:

  • To investigate the role of PARP-1 in ESFT pathogenesis.
  • To evaluate the efficacy of PARP-1 inhibition as a therapeutic strategy for ESFT.

Main Methods:

  • Assessed the sensitivity of ESFT cells, xenografts, and metastases to PARP1 inhibition.
  • Investigated the mechanistic link between EWS-FLI1/EWS-ERG fusions and PARP-1.
  • Evaluated the combination of a PARP1 inhibitor and temozolamide in a preclinical ESFT model.

Main Results:

  • ESFTs exhibited high sensitivity to PARP1 inhibition across cellular, xenograft, and metastatic models.
  • PARP1 inhibition potentiated DNA damage induced by EWS-FLI1/EWS-ERG.
  • A combination therapy of a PARP1 inhibitor and temozolamide achieved complete tumor responses in an EWS-FLI1-driven xenograft model.
  • EWS-FLI1 demonstrated a positive feedback loop, maintaining PARP1 expression essential for oncogenic transcription.

Conclusions:

  • Targeting the EWS-FLI1:PARP1 interaction presents a promising therapeutic strategy for ESFT.
  • PARP1 inhibition, particularly in combination with temozolamide, shows significant preclinical efficacy against ESFT.

More Related Videos

In Vivo Model for Testing Effect of Hypoxia on Tumor Metastasis12:03

In Vivo Model for Testing Effect of Hypoxia on Tumor Metastasis

Published on: December 9, 2016

Targeted and Selective Treatment of Pluripotent Stem Cell-derived Teratomas Using External Beam Radiation in a Small-animal Model05:08

Targeted and Selective Treatment of Pluripotent Stem Cell-derived Teratomas Using External Beam Radiation in a Small-animal Model

Published on: February 17, 2019

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...